SCHEMBL15526532

SCHEMBL15526532

COc1ncc([C@](C)(O)C(F)(F)F)cc1Br

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.36
PIK3CA P42336 2/20 0.36
MTOR P42345 1/20 0.36
S100A9 P06702 1/20 0.36
CETP P11597 1/20 0.35
RAB9A P51151 1/20 0.35
GCK P35557 3/20 0.33
GCKR Q14397 3/20 0.33
RXRA P19793 1/20 0.32
GRIN1 Q05586 1/20 0.32
GRIN2B Q13224 1/20 0.32
CYP11B1 P15538 4/20 0.32
CYP11B2 P19099 4/20 0.32
CYP19A1 P11511 3/20 0.32
CYP2C9 P11712 3/20 0.32
ULK1 O75385 1/20 0.32
HDAC3 O15379 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15526446 1.00 HSD11B1 (0.36) HSD11B1PIK3CAMTORS100A9CETP
SCHEMBL7916612 0.82 CYP1A2 (0.43) S100A9RAB9AULK1HDAC3HDAC1
SCHEMBL29837917 0.82 CYP1A2 (0.43) S100A9RAB9AULK1HDAC3HDAC1
SCHEMBL31525360 0.80 S100A9 (0.35) PIK3CAMTORS100A9CYP2C9ULK1
SCHEMBL21544759 0.78 BRD4 (0.45) HSD11B1RAB9ACYP11B1CYP11B2
SCHEMBL31614299 0.74 S100A9 (0.37) PIK3CAS100A9CYP11B1CYP11B2HDAC3
SCHEMBL16650030 0.69 PIK3CA (0.47) HSD11B1PIK3CAMTORGCKGCKR
SCHEMBL15526479 0.69 PIK3CA (0.47) HSD11B1PIK3CAMTORGCKGCKR
SCHEMBL933336 0.69 S100A9 (0.36) PIK3CAMTORS100A9CYP2C9ULK1
SCHEMBL29965383 0.69 ALOX5 (0.44) PIK3CAMTORS100A9HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2844252-B1 CYCLIC AMINE SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CETP INHIBITORS MERCK SHARP & DOHME (US) 2016-11-30 EP disclosed
US-9353101-B2 Cyclic amine substituted heterocyclic CETP inhibitors MERCK SHARP & DOHME CORP. (US) 2016-05-31 US disclosed
US-20150111866-A1 CYCLIC AMINE SUBSTITUTED HETEROCYCLIC CETP INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-23 US disclosed
EP-2844252-A1 CYCLIC AMINE SUBSTITUTED HETEROCYCLIC CETP INHIBITORS Merck Sharp & Dohme Corp. (US) 2015-03-11 EP disclosed
WO-2013165854-A1 CYCLIC AMINE SUBSTITUTED HETEROCYCLIC CETP INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-11-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150111866-A1 CYCLIC AMINE SUBSTITUTED HETEROCYCLIC CETP INHIBITORS CETP, APOB, MTTP HSD11B1 474/4885PIK3CA 3210/4885MTOR 2319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.